With Phase 3 Studies Ongoing in Bladder Cancer, CG Oncology Plots Course for IPO
CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follow the report of interim efficacy data showing a 75% complete response rate.
United States Exchange Commission Renaissance Capital Bacillus Calmette Gu Urologic Oncology Cold Genesys
Source: medcitynews.com